Ventus Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule medicines for inflammatory and immune-mediated disease. Public materials highlight its ReSOLVE® structural biology and computational chemistry platform and pipeline programs directed at innate immune targets. Its disclosed lead assets include NLRP3 and cGAS inhibitors being developed for neurological, inflammatory, and autoimmune indications.